TNFRSF10C

From Wikipedia, the free encyclopedia


Tumor necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain
Identifiers
Symbol(s) TNFRSF10C; CD263; DCR1; LIT; MGC149501; MGC149502; TRAILR3; TRID
External IDs OMIM: 603613 HomoloGene: 48244
RNA expression pattern

More reference expression data
Orthologs
Human Mouse
Entrez 8794 n/a
Ensembl ENSG00000173535 n/a
Uniprot O14798 n/a
Refseq NM_003841 (mRNA)
NP_003832 (protein)		 n/a (mRNA)
n/a (protein)
Location Chr 8: 23.02 - 23.03 Mb n/a
Pubmed search [1] n/a

Tumor necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain, also known as TNFRSF10C, is a human gene.[1]

The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor contains an extracellular TRAIL-binding domain and a transmembrane domain, but no cytoplasmic death domain. This receptor is not capable of inducing apoptosis, and is thought to function as an antagonistic receptor that protects cells from TRAIL-induced apoptosis. This gene was found to be a p53-regulated DNA damage-inducible gene. The expression of this gene was detected in many normal tissues but not in most cancer cell lines, which may explain the specific sensitivity of cancer cells to the apoptosis-inducing activity of TRAIL.[1]

[edit] References

  1. ^ a b Entrez Gene: TNFRSF10C tumor necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain.

[edit] Further reading

  • Kimberley FC, Screaton GR (2005). "Following a TRAIL: update on a ligand and its five receptors.". Cell Res. 14 (5): 359–72. doi:10.1038/sj.cr.7290236. PMID 15538968. 
  • Pan G, Ni J, Wei YF, et al. (1997). "An antagonist decoy receptor and a death domain-containing receptor for TRAIL.". Science 277 (5327): 815–8. PMID 9242610. 
  • Sheridan JP, Marsters SA, Pitti RM, et al. (1997). "Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors.". Science 277 (5327): 818–21. PMID 9242611. 
  • Degli-Esposti MA, Smolak PJ, Walczak H, et al. (1997). "Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family.". J. Exp. Med. 186 (7): 1165–70. PMID 9314565. 
  • MacFarlane M, Ahmad M, Srinivasula SM, et al. (1997). "Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL.". J. Biol. Chem. 272 (41): 25417–20. PMID 9325248. 
  • Schneider P, Bodmer JL, Thome M, et al. (1997). "Characterization of two receptors for TRAIL.". FEBS Lett. 416 (3): 329–34. PMID 9373179. 
  • Mongkolsapaya J, Cowper AE, Xu XN, et al. (1998). "Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL.". J. Immunol. 160 (1): 3–6. PMID 9551946. 
  • Rieger J, Naumann U, Glaser T, et al. (1998). "APO2 ligand: a novel lethal weapon against malignant glioma?". FEBS Lett. 427 (1): 124–8. PMID 9613612. 
  • Sheikh MS, Huang Y, Fernandez-Salas EA, et al. (1999). "The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract.". Oncogene 18 (28): 4153–9. doi:10.1038/sj.onc.1202763. PMID 10435597. 
  • Leverkus M, Walczak H, McLellan A, et al. (2000). "Maturation of dendritic cells leads to up-regulation of cellular FLICE-inhibitory protein and concomitant down-regulation of death ligand-mediated apoptosis.". Blood 96 (7): 2628–31. PMID 11001921. 
  • Zhang XD, Nguyen T, Thomas WD, et al. (2000). "Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types.". FEBS Lett. 482 (3): 193–9. PMID 11024459. 
  • Dörr J, Bechmann I, Waiczies S, et al. (2002). "Lack of tumor necrosis factor-related apoptosis-inducing ligand but presence of its receptors in the human brain.". J. Neurosci. 22 (4): RC209. PMID 11844843. 
  • Liao Q, Friess H, Kleeff J, Büchler MW (2002). "Differential expression of TRAIL-R3 and TRAIL-R4 in human pancreatic cancer.". Anticancer Res. 21 (5): 3153–9. PMID 11848467. 
  • Bretz JD, Mezosi E, Giordano TJ, et al. (2002). "Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells.". Cell Death Differ. 9 (3): 274–86. doi:10.1038/sj/cdd/4400965. PMID 11859410. 
  • Hueber A, Aduckathil S, Kociok N, et al. (2002). "Apoptosis-mediating receptor-ligand systems in human retinal pigment epithelial cells.". Graefes Arch. Clin. Exp. Ophthalmol. 240 (7): 551–6. doi:10.1007/s00417-002-0487-6. PMID 12136286. 
  • Matysiak M, Jurewicz A, Jaskolski D, Selmaj K (2002). "TRAIL induces death of human oligodendrocytes isolated from adult brain.". Brain 125 (Pt 11): 2469–80. PMID 12390973. 
  • Ruiz de Almodóvar C, López-Rivas A, Redondo JM, Rodríguez A (2002). "Transcription initiation sites and promoter structure of the human TRAIL-R3 gene.". FEBS Lett. 531 (2): 304–8. PMID 12417331. 
  • Strausberg RL, Feingold EA, Grouse LH, et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMID 12477932. 
  • Ou D, Metzger DL, Wang X, et al. (2003). "TNF-related apoptosis-inducing ligand death pathway-mediated human beta-cell destruction.". Diabetologia 45 (12): 1678–88. doi:10.1007/s00125-002-0926-2. PMID 12488957. 
  • Hasel C, Dürr S, Rau B, et al. (2003). "In chronic pancreatitis, widespread emergence of TRAIL receptors in epithelia coincides with neoexpression of TRAIL by pancreatic stellate cells of early fibrotic areas.". Lab. Invest. 83 (6): 825–36. PMID 12808117. 
 This membrane protein-related article is a stub. You can help Wikipedia by expanding it.

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

v • d • e
Proteins: clusters of differentiation (see also list of human clusters of differentiation)
1-50
CD1 (a-c, 1A, 1D, 1E) - CD2 - CD3 (γ, δ, ε) - CD4 - CD5 - CD6 - CD7 - CD8 (a) - CD9 - CD10 - CD11 (a, b, c) - CD13 - CD14 - CD15 - CD16 (A, B) - CD18 - CD19 - CD20 - CD21 - CD22 - CD23 - CD24 - CD25 - CD26 - CD27 - CD28 - CD29 - CD30 - CD31 - CD32 (A, B) - CD33 - CD34 - CD35 - CD36 - CD37 - CD38 - CD39 - CD40 - CD41- CD42 (a, b, c, d) - CD43 - CD44 - CD45 - CD46 - CD47 - CD48 - CD49 (a, b, c, d, e, f) - CD50
51-100
CD51 - CD52 - CD53 - CD54 - CD55 - CD56 - CD57- CD58 - CD59 - CD61 - CD62 (E, L, P) - CD63 - CD64 - CD66 (a, b, c, d, e, f) - CD68 - CD69 - CD70 - CD71 - CD72 - CD73 - CD74 - CD79 (a, b) - CD80 - CD81 - CD82 - CD83 - CD84 - CD85 (a, d, e, h, j, k) - CD86 - CD87 - CD88 - CD89 - CD90 - CD91- CD92 - CD93 - CD94 - CD95 - CD97 - CD98 - CD99 - CD100
101-150
CD101 - CD102 - CD103 - CD104 - CD105 - CD106 - CD107 (a, b) - CD108 - CD109 - CD110 - CD111 - CD112 - CD113 - CD114 - CD115 - CD116 - CD117 - CD118 - CD119 - CD120 (a, b) - CD121 (a, b) - CD122 - CD123 - CD124 - CD125 - CD126 - CD127 - CD129 - CD130 - CD131 - CD132 - CD133 - CD134 - CD135 - CD136 - CD137 - CD138 - CD140b - CD141 - CD142 - CD143 - CD144 - CD146 - CD147 - CD148 - CD150
151-200
CD151 - CD152 - CD153 - CD154 - CD155 - CD156 (a, b, c) - CD157 - CD158 (a, d, e, i, k) - CD159 (a, c) - CD160 - CD161 - CD162 - CD163 - CD164 - CD166 - CD167 (a, b) - CD168 - CD169 - CD170 - CD171 - CD172 (a, b, g) - CD174 - CD177 - CD178 - CD179 (a, b) - CD181 - CD182 - CD183 - CD184 - CD185 - CD186 - CD191 - CD192 - CD193 - CD194 - CD195 - CD196 - CD197 - CDw198 - CDw199 - CD200
201-250
CD201 - CD202b - CD204 - CD205 - CD206 - CD207 - CD208 - CD209 - CDw210 (a, b) - CD212 - CD213a (1, 2) - CD217 - CD218 (a, b) - CD220 - CD221 - CD222 - CD223 - CD224 - CD225 - CD226 - CD227 - CD228 - CD229 - CD230 - CD233 - CD234 - CD235 (a, b) - CD236 - CD238 - CD239 - CD240CE - CD241 - CD243 - CD244 - CD246 - CD247- CD248 - CD249
251-300
301-350
v • d • e
Cytokine receptors: tumor necrosis factor receptor superfamily
1-10
11-20
21-25